DDInter1476 DDInter817
Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3†,5†-adenosine monophosphate (c-
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Pirbuterol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gilteritinib
Pirbuterol {u} (Compound) resembles {v} (Compound) Terbutaline
Terbutaline {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gilteritinib
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentamidine
Pentamidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Pirbuterol {u} (Compound) resembles {v} (Compound) Nadolol
Nadolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Deutetrabenazine
Deutetrabenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Pirbuterol {u} (Compound) resembles {v} (Compound) Epinephrine
Epinephrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Pirbuterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Pirbuterol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Pirbuterol (Compound) resembles Terbutaline (Compound) and Terbutaline (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Pirbuterol (Compound) resembles Nadolol (Compound) and Nadolol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine and Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Pirbuterol (Compound) resembles Epinephrine (Compound) and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Pirbuterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib